PPARG and obesity due to melanocortin 4 receptor deficiency: Considering the clearly demonstrated results of in-vitro and in-vivo studies, an emphasizing pharmacological efficiency of BSTN1 against obesity and dyslipidemia is elucidated via PPAR-γ and AMPK modulation.